A power shift at Lykos Therapeutics could revive MDMA-assisted therapy—and Rick Doblin’s influence. Here’s what’s changing, why it matters, and how DMV residents should watch the next moves.

A tightly controlled New Zealand program lets two psychiatrists prescribe pharmaceutical-grade MDMA for select adults with PTSD. Here’s how it works, the evidence behind it, and what DMV readers should watch.

Resilient Pharmaceuticals submits a renewed application for MDMA-assisted PTSD therapy, seeking FDA approval without a fresh Phase 3 trial.

An in-depth look at ICPR 2026 research, clinical trial findings, regulatory hurdles, and implications for medical cannabis and patient care.

Resilient resubmits MDMA-assisted therapy to FDA, Definium reports positive oral LSD Phase 3 data in GAD, and Canada funds a C$24M cannabis–brain health consortium.